Physiologically-based pharmacokinetics (PBPK) modeling is a robust tool that supports drug
development and the pharmaceutical industry and regulatory authorities. Implementation of …

Abstract Background and Objective The US Food and Drug Administration (FDA) has seen a
recent increase in the application of physiologically based pharmacokinetic (PBPK) …

According to current US Food and Drug Administration (FDA) and European Medicines
Agency (EMA) guidance documents, physiologically based pharmacokinetic (PBPK) …

Intestinal transporters and enzymes are factors that can influence the absorption of orally
administrated drugs. Compartmental models are no longer adequate to describe the …

The occurrence of drug–drug interactions (DDIs) can significantly affect the safety of a
patient, and thus assessing DDI risk is important. Recently, physiologically based …

The gold‐standard approach for modeling pharmacokinetic mediated drug–drug
interactions is the use of physiologically‐based pharmacokinetic modeling and population …

Early prediction of human pharmacokinetics (PK) and drug–drug interactions (DDI) in drug
discovery and development allows for more informed decision making. Physiologically …

From the year 2000 onwards, physiologically based pharmacokinetic (PBPK) models in the
field of drug research and development have been increasingly used. This proliferation of …

Modeling and simulation of drug disposition has emerged as an important tool in drug
development, clinical study design and regulatory review, and the number of physiologically …

Physiologically based pharmacokinetic (PBPK) modeling and simulation can be used to
predict the pharmacokinetic behavior of drugs in humans using preclinical data. It can also …